AGAPE ATP CORPORATION Net Income (Loss) Attributable to Noncontrolling Interest
AGAPE ATP CORPORATION (ATPC) reported Net Income (Loss) Attributable to Noncontrolling Interest of $3.57 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-14
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was $3.57K, a 42.19% decline year-over-year.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $13.29K, a 4.89% decline year-over-year.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $865.00.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$8.54K.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$27.82K.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$15.57K.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$7.95K, a 138.18% decline from fiscal 2022.
- AGAPE ATP CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2022 was $20.82K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.57K 10-Q · filed 2026-08-14 | $16.85K 10-Q · filed 2026-08-14 | $17.72K derived: sum of 3 quarters · filed 2026-08-14 | $9.18K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $13.29K 10-Q · filed 2026-05-15 | $14.15K derived: sum of 2 quarters · filed 2026-05-15 | $5.61K derived: sum of 3 quarters · filed 2026-05-15 | $11.78K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $865.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-13 | -$7.68K derived: sum of 2 quarters · filed 2026-04-13 | -$1.51K derived: sum of 3 quarters · filed 2026-08-14 | -$27.82K 10-K · filed 2026-04-13 | ||
| 2025-09-30 | -$8.54K 10-Q · filed 2025-11-13 | -$2.38K derived: sum of 2 quarters · filed 2026-08-14 | -$28.68K 10-Q · filed 2025-11-13 | -$6.56K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $6.17K 10-Q · filed 2026-08-14 | -$6.17K 10-Q · filed 2025-08-13 | $20.14K 10-Q · filed 2026-08-14 | -$20.14K 10-Q · filed 2025-08-13 | $1.98K derived: sum of 3 quarters · filed 2026-08-14 | -$12.43K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $13.97K 10-Q · filed 2026-05-15 | -$13.97K 10-Q · filed 2025-05-15 | -$4.19K derived: sum of 2 quarters · filed 2026-05-15 | -$18.60K derived: sum of 3 quarters · filed 2026-05-15 | -$8.21K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$18.16K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-13 | -$32.57K derived: sum of 2 quarters · filed 2026-04-13 | -$22.18K derived: sum of 3 quarters · filed 2026-04-13 | -$15.57K 10-K · filed 2026-04-13 | ||
| 2024-09-30 | -$14.41K 10-Q · filed 2025-11-13 | -$4.03K derived: sum of 2 quarters · filed 2025-11-13 | $2.59K 10-Q · filed 2025-11-13 | $5.34K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $10.38K 10-Q · filed 2025-08-13 | $17.00K 10-Q · filed 2025-08-13 | $19.75K derived: sum of 3 quarters · filed 2025-08-13 | $22.05K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $6.61K 10-Q · filed 2025-05-15 | $9.37K derived: sum of 2 quarters · filed 2025-05-15 | $11.66K derived: sum of 3 quarters · filed 2025-05-15 | $6.90K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $2.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.05K derived: sum of 2 quarters · filed 2025-03-31 | $285.00 derived: sum of 3 quarters · filed 2025-03-31 | -$7.95K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $2.29K 10-Q · filed 2024-11-14 | -$2.47K derived: sum of 2 quarters · filed 2024-11-14 | -$10.70K 10-Q · filed 2024-11-14 | -$1.59K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$4.76K 10-Q · filed 2024-08-14 | -$13.00K 10-Q · filed 2024-08-14 | -$3.88K derived: sum of 3 quarters · filed 2024-08-14 | -$3.39K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$8.23K 10-Q · filed 2024-05-14 | $881.00 derived: sum of 2 quarters · filed 2024-05-14 | $1.38K derived: sum of 3 quarters · filed 2024-05-14 | $11.93K derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $9.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $9.61K derived: sum of 2 quarters · filed 2024-04-01 | $20.17K derived: sum of 3 quarters · filed 2024-04-01 | $20.82K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $495.00 10-Q · filed 2023-11-14 | $11.05K derived: sum of 2 quarters · filed 2023-11-14 | $11.70K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $10.56K 10-Q · filed 2023-08-14 | $11.21K 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $651.00 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | -$436.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |